FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.
What happened
FDA reviewed records Babikian submitted after FDA's August 12, 2025 request for records under section 704(a)(4) of the FD&C Act. FDA said the firm did not test each incoming component's identity, relied on supplier certificates without verifying them, and lacked finished-product tests for identity, strength, impurities, and microorganisms. FDA also said the quality unit failed to ensure procedures, batch records, stability data, and authority.
What FDA found
The firm did not test the identity of each incoming component before use and did not verify its suppliers' test results at appropriate intervals.
21 CFR 211.84(d)(1) & 211.84(d)(2)The firm did not test each finished batch for identity and strength of active ingredients, impurities, and objectionable microorganisms before release.
21 CFR 211.165(a) and 211.165(b)The quality unit did not ensure written production and process control procedures, qualification of a system producing a drug component, complete batch records, stability data, and adequate authority and procedures.
21 CFR 211.22; 21 CFR 211.100(a); 21 CFR 211.188; 21 CFR 211.137(a); 21 CFR 211.22(a) & 211.22(d)A second Babikian establishment listed as manufacturer of record for U.S. shipments was not registered with FDA as a drug establishment.
section 510(i) of the FD&C Act and 21 CFR 207.17(a)
What FDA wants
FDA tells the company to send a written response within 15 business days to CDER-OC-OMQ-Communications@fda.hhs.gov, identify FEI 3027526825, address root causes and corrective actions, and engage a qualified CGMP consultant.
Who should pay attention
- U.S. companies importing or distributing OTC drugs made by this firm
- brands using Babikian as a contract manufacturer or manufacturer of record
- buyers relying on supplier certificates of analysis for active ingredients
This is a summary. Read the original letter on fda.gov.